ABSTRACT
BACKGROUND: Lead protective gloves are widely used to attenuate scattered radiations during fluoroscopic-guided medical procedures, thereby reducing hand exposure to radiation. AIMS: To determine whether lead-containing gloves present a risk of metal leaching onto the operator's skin, particularly due to the presence of sweat. METHODS: Artificial sweat of varying acidity was introduced into two types of commercial gloves containing lead. The level of lead in the sweat was then assessed after different exposure times. Electron microscopy was used to observe the morphology of the glove layers. RESULTS: Lead was detected in artificial sweat during each contact test on two different types of gloves. The concentration of lead increased with the acidity of the sweat, and the contact time. Gloves with a protective lining transferred less lead into sweat, but it was still present at significant levels. (i.e. few milligrams of lead per glove after one hour contact). CONCLUSIONS: Fluoroscopy operators should be aware of the risk of leaching of lead ions when using lead gloves under intensive conditions, although the potential harmfulness of lead ions leached into the glove remains essentially unknown.
Subject(s)
Gloves, Protective , Sweat , Humans , IonsABSTRACT
INTRODUCTION: Restaging transurethral resection (re-TUR) of high grade T1 bladder cancer (HGT1-BC) is recommended but the impact in terms of recurrence-free survival (RFS) and progression-free survival (PFS) is discussed. The objective of this study was to evaluate our practice of re-TUR for these tumors and its impact on overall survival (OS), RFS and PFS. MATERIALS AND METHODS: A retrospective observational study was conducted between 2010 and 2020. The inclusion criteria was the presence of newly diagnosed HGT1-BC. Patients with incomplete resection, suspicion of infiltrating tumor, upper tract urothelial cancer, or metastatic disease were ineligible. Two groups were defined : Group 1 with re-TUR and Group 2 without re-TUR. RFS and PFS were evaluated. RESULTS: A total of 78 patients were included, including 50 (64,1%) in group 1. There were no significant differences between the two groups. The mean time to re-TUR was 8 weeks and 60% residual tumor was found. Initial under-staging was found in 12% of cases. RFS and PFS were significantly better in Group 1 (P=0.0019; P=0,02). No significant were found between the groups in OS and specific survival (SS). CONCLUSION: Performing a re-TUR for high grade T1 bladder tumors allows detection of residual tumor and decreases the risk of under-evaluation. It is associated with a significant improvement in RFS and PFS with no impact on OS and SS.
Subject(s)
Urinary Bladder Neoplasms , Urinary Bladder , Humans , Progression-Free Survival , Neoplasm, Residual/pathology , Neoplasm, Residual/surgery , Neoplasm Staging , Urinary Bladder/pathology , Urinary Bladder Neoplasms/pathology , Retrospective Studies , Neoplasm Recurrence, Local/surgery , CystectomyABSTRACT
INTRODUCTION: Colchicine is a narrow therapeutic margin drug that does not have the adverse effects of corticosteroids and immunosuppressants. Its use in non-severe ocular inflammatory disease excluding Behcet's disease has not been studied. METHODS: We included patients seen in the internal medicine department of Dijon University Hospital consecutively between September 2020 and September 2021 if they had received colchicine during their pathology. Patients with suspected Behçet's disease were excluded. Treatment efficacy was studied in patients with at least one year of disease progression who had received more than one year of colchicine. Successful treatment was defined as a 50 % reduction in the number of annual relapses on colchicine. RESULTS: Sixteen patients were included (9 women and 7 men). They had recurrent anterior uveitis (n=10), recurrent scleritis (n=5) and intermediate uveitis. Opthalmological involvement was neither severe nor complicated. All patients combined, the annual relapse ratio (ARR) decreased from 1.8 (0.8-3.5) to 0.3 (0-1.6), (P=0.06). Colchicine was considered effective in three of 10 analyzable patients. In only one patient, treatment was stopped for adverse effects after six weeks. CONCLUSION: In view of the interesting benefit-risk ratio of colchicine, it seems appropriate to focus on this molecule in non-granulomatous anterior uveitis and non-severe recurrent scleritis.
Subject(s)
Behcet Syndrome , Scleritis , Uveitis, Anterior , Uveitis , Male , Humans , Female , Behcet Syndrome/complications , Behcet Syndrome/diagnosis , Behcet Syndrome/drug therapy , Colchicine/adverse effects , Scleritis/diagnosis , Scleritis/drug therapy , Scleritis/etiology , Vision Disorders , Uveitis, Anterior/complications , Uveitis, Anterior/drug therapy , Recurrence , Inflammation/complications , Uveitis/diagnosis , Uveitis/drug therapy , Uveitis/etiologySubject(s)
Health Facility Merger/organization & administration , Hospitals, Religious/organization & administration , Multi-Institutional Systems/organization & administration , Organizational Culture , Catholicism , Leadership , Michigan , Missouri , Planning Techniques , Social Values , Systems Integration , United States , WorkforceABSTRACT
Bone powder from patients dying with chronic renal failure of more than 1 yr duration was shown to release less calcium and more phosphate when equilibrated with a buffer solution. pH 7.4 at 4 degrees C. This change persisted after removal of the organic component and was associated with a reduction in the bone carbonate content. Crystal size and surface area showed no consistent changes from the controls and it was concluded that an alteration in the apatite crystal composition had occurred in long-standing uremia with carbonate-phosphate interchange. Support for this was provided by synthesis of apatites which were carbonate deficient and behaved in a similar manner to the uremic bones.
